Wyeth-Ayerst Prempro/Premphase single tablets will replace current products in early 1996.
WYETH-AYERST PREMPRO/PREMPHASE SINGLE-TABLET FORMULATION for hormone replacement therapy will be launched in the first quarter of 1996. The single-tablet version of the combination conjugated estrogens and medroxyprogesterone product cleared FDA on Nov. 17. Data from several trials show that when progestin is added to estrogen therapy the risk of uterine cancer in nonhysterectomized women is reduced.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth